Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.85USD
27 Jul 2016
Change (% chg)

$0.02 (+0.05%)
Prev Close
$36.83
Open
$36.75
Day's High
$36.92
Day's Low
$36.65
Volume
15,064,000
Avg. Vol
33,753,020
52-wk High
$37.19
52-wk Low
$28.25

PFE

Chart for PFE

About

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor,... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $223,368.41
Shares Outstanding(Mil.): 6,064.85
Dividend: 0.30
Yield (%): 3.26

Financials

  PFE Industry Sector
P/E (TTM): 30.18 36.73 37.52
EPS (TTM): 1.22 -- --
ROI: 5.56 15.28 14.48
ROE: 11.65 16.33 15.65

UPDATE 2-Incoming Lilly CEO says dealmaking will be a focus

July 27 Eli Lilly & Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday.

2:46pm EDT

Bayer drugs secure earnings beat, offset weak crop chems

FRANKFURT Bayer , the German drugmaker trying to acquire U.S. seed company Monsanto , surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.

2:45am EDT

UPDATE 1-Bayer drugs secure earnings beat, offset weak crop chems

* Shares seen up 0.7 pct in premarket trades (Adds details on Xarelto, Eylea, Crop Chemicals unit, background on Monsanto)

2:43am EDT

BRIEF-Bind Therapeutics determines Pfizer's $40 mln bid highest

* Plans to disclose additional terms of its agreement with Pfizer upon court approval.

Jul 26 2016

Exclusive: Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.

Jul 26 2016

BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial

* Spark Therapeutics and Pfizer announce updated data from first cohort in Hemophilia B phase 1/2 trial demonstrating consistent, sustained therapeutic levels of factor ix activity

Jul 25 2016

BRIEF-Bind Therapeutics says two bidders join Pfizer's stalking horse bid

* Bids are in addition to pfizer inc.'s initial stalking horse bid of approximately $20 million under section 363 of u.s. Bankruptcy code

Jul 25 2016

BRIEF-Pfizer gets WHO prequalification for multi-dose vial presentation of Prevenar 13

* Pfizer receives world health organization prequalification for multi-dose vial presentation of Prevenar 13

Jul 19 2016

DEALTALK-Old pharma sees new profit cure in cancer drugs

July 19 Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

Old pharma sees new profit cure in cancer drugs

Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.77 -0.38
Novartis AG (NOVN.S) CHF81.90 -0.60
Merck & Co., Inc. (MRK.N) $58.60 +0.24
Roche Holding Ltd. (ROG.S) CHF249.30 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -1.25
Abbott Laboratories (ABT.N) $43.67 +0.07
Bayer AG (BAYGn.DE) €94.62 +1.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.70 +0.13
AstraZeneca plc (AZN.L) 4,690.00p +51.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.